Last update 24 May 2025

HS-630

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
HS630
Target
HER2 x Tubulin
Action
antagonists, inhibitors
Mechanism
HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), Tubulin inhibitors, ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)
Therapeutic Areas
NeoplasmsSkin and Musculoskeletal Diseases
Active Indication
HER2 Positive Breast CancerLocally advanced breast cancerMetastatic breast cancer
Inactive Indication-
Originator Organization
Zhejiang Hisun Pharmaceutical Co., Ltd.Zhejiang Hisun Pharmaceutical Co., Ltd.
Active Organization
Beijing Mabworks Biotech Co., Ltd.Beijing Mabworks Biotech Co., Ltd.Zhejiang Hisun Pharmaceutical Co., Ltd.Zhejiang Hisun Pharmaceutical Co., Ltd.
Inactive Organization-
License Organization
Zhejiang Hisun Pharmaceutical Co., Ltd.Zhejiang Hisun Pharmaceutical Co., Ltd.BioRay Biopharmaceutical Co., Ltd.BioRay Biopharmaceutical Co., Ltd.
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC35H48ClN3O10S
InChIKeyANZJBCHSOXCCRQ-FKUXLPTCSA-N
CAS Registry139504-50-0
View All Structures (2)
Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

1
Clinical Trials associated with HS-630
CTR20181755
/ RecruitingPhase 1
重组抗HER2人源化单克隆抗体偶联美登素衍生物DM1注射液
[Translation] Recombinant anti-HER2 humanized monoclonal antibody coupled with maytansine derivative DM1 injection
100 Clinical Results associated with HS-630
Login to view more data
100 Translational Medicine associated with HS-630
Login to view more data
100 Patents (Medical) associated with HS-630
Login to view more data
100 Deals associated with HS-630
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HER2 Positive Breast CancerPhase 1
China
Beijing Mabworks Biotech Co., Ltd.Beijing Mabworks Biotech Co., Ltd.
26 Sep 2019
HER2 Positive Breast CancerPhase 1
China
Zhejiang Hisun Pharmaceutical Co., Ltd.Zhejiang Hisun Pharmaceutical Co., Ltd.
26 Sep 2019
Locally advanced breast cancerPhase 1
China
Zhejiang Hisun Pharmaceutical Co., Ltd.Zhejiang Hisun Pharmaceutical Co., Ltd.
26 Sep 2019
Locally advanced breast cancerPhase 1
China
Beijing Mabworks Biotech Co., Ltd.Beijing Mabworks Biotech Co., Ltd.
26 Sep 2019
Metastatic breast cancerPhase 1
China
Beijing Mabworks Biotech Co., Ltd.Beijing Mabworks Biotech Co., Ltd.
26 Sep 2019
Metastatic breast cancerPhase 1
China
Zhejiang Hisun Pharmaceutical Co., Ltd.Zhejiang Hisun Pharmaceutical Co., Ltd.
26 Sep 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free